Breaking News Instant updates and real-time market news.

OBSV

ObsEva

$12.52

0.25 (2.04%)

, ABBV

AbbVie

$97.29

-0.73 (-0.74%)

07:51
08/29/18
08/29
07:51
08/29/18
07:51

AbbVie study of elagolix reduces risk for ObsEva, says H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju believes AbbVie's (ABBV) long-term safety extension study of elagolix in women with uterine fibroids reduces risk for ObsEva (OBSV). The long-term efficacy for elagolix should bode well for future development of ObsEva's linzagolix in uterine fibroids, since both drugs are gonadotropin-releasing hormone receptor antagonists and have thus far shown comparable potency in clinical studies, Selvaraju tells investors in a research note. The analyst reiterates a Buy rating on ObsEva with a $44 price target.

OBSV

ObsEva

$12.52

0.25 (2.04%)

ABBV

AbbVie

$97.29

-0.73 (-0.74%)

  • 04

    Sep

  • 05

    Sep

  • 12

    Sep

OBSV ObsEva
$12.52

0.25 (2.04%)

08/07/18
08/07/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Broadcom (AVGO) reinstated with an Overweight at Barclays. 2. ObsEva (OBSV) initiated with an Outperform at Wedbush. 3. Deciphera (DCPH) initiated with a Buy at Canaccord. 4. Alliance Data (ADS) assumed with a Buy at Jefferies. 5. Hermes (HESAY) initiated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/18
HCWC
08/08/18
NO CHANGE
Target $44
HCWC
Buy
ObsEva price target raised to $44 from $30 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for ObsEva (OBSV) to $44 based on the disclosed pricing for AbbVie's (ABBV) Orilissa, the fgonadotropin-releasing hormone receptor antagonist for endometriosis and uterine fibroids. ObsEva management had previously guided to the cost of GnRH receptor antagonist therapy at $15 per day, about $450 per month, and the proposed monthly cost of Orilissa at $845 "appears to be comfortably above this level," Selvaraju tells investors in a research note. As such, the analyst elected to revise his pricing assumptions upward for ObsEva's linzagolix to reflect a daily cost of $25. He keeps a Buy rating on ObsEva shares.
08/15/18
LEER
08/15/18
INITIATION
Target $25
LEER
Outperform
ObsEva resumed with an Outperform at Leerink
Leerink analyst Ami Fadia resumed coverage of ObsEva with an Outperform rating and $25 price target. The analyst believes that at current levels the stock does not fully reflect the commercial potential of its lead product linzagolix, which she believes can reach over $1B in peak sales, its additional women's health pipeline, and its more than $100M cash balance that can fund operation into 1H20, by which time she expects to get positive UF Phase 3 data readout for linzagolix.
08/15/18
08/15/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cision (CISN) initiated with an Outperform at William Blair. 2. ObsEva (OBSV) resumed with an Outperform at Leerink. 3. Idera Pharmaceuticals (IDRA) resumed with an Overweight at JPMorgan. 4. DTE Energy (DTE) initiated with an Equal Weight at Barclays. 5. Tellurian (TELL) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ABBV AbbVie
$97.29

-0.73 (-0.74%)

07/24/18
SBSH
07/24/18
NO CHANGE
SBSH
Buy
Citi says Myovant may have $102 upside if relugolix priced at parity to elagolix
After AbbVie (ABBV) and Neurocrine Biosciences (NBIX) announced that the FDA approved elagolix and Neurocrine said the list price has been set at $28 per day, Citi analyst Robyn Karnauskas noted that she currently models Myovant Sciences' (MYOV) relugolix priced at $10 per day. Modeling relugolix pricing at parity to elagolix and assuming a gross-to-net of 100% would lead to a fair value estimate for Myovant of $146, or the equivalent of $102 of upside from her current price target of $44, Karnauskas stated. The analyst, who models a split market between relugolix and elagolix in endometriosis, keeps a Buy rating on Myovant shares.
07/27/18
PIPR
07/27/18
NO CHANGE
Target $100
PIPR
Neutral
Worries about AbbVie's Humira keep Piper Jaffray on sidelines
Piper Jaffray analyst Christopher Raymond said he finds "little to quibble with" in AbbVie's Q2 report, but also noted that while its FY18 EPS guidance was raised, its revenue guidance actually came down slightly. Raymond, who continues to worry that consensus does not fully factor in the extent of ex-U.S. Humira pressure or the further pressure from co-pay accumulator programs in the U.S., prefers to stay on the sidelines and keeps a Neutral rating on the shares. He also lowered his price target on AbbVie to $100 from $105.
08/22/18
PIPR
08/22/18
NO CHANGE
Target $130
PIPR
Overweight
AbbVie decision suggests positive Argenx data, says Piper Jaffray
AbbVie's (ABBV) decision to exercise an exclusive option to license Argenx's (ARGX) anti-GARP antibody, ARGX-115, suggests positive preclinical data, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. The analyst looks for investigational new drug application filing plans this year. He reiterates an Overweight rating on shares of Argenx with a $130 price target.

TODAY'S FREE FLY STORIES

MCO

Moody's

$172.88

-2.66 (-1.52%)

16:31
09/25/18
09/25
16:31
09/25/18
16:31
Hot Stocks
Moody's appoints Mona Breed as CIO »

Moody's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 28

    Sep

  • 02

    Oct

  • 21

    Oct

FCFS

First Cash Financial

$83.03

0.625 (0.76%)

16:31
09/25/18
09/25
16:31
09/25/18
16:31
Hot Stocks
First Cash Financial announces move to Nasdaq from NYSE »

FirstCash announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 06

    Nov

OKE

Oneok

$68.44

0.565 (0.83%)

16:31
09/25/18
09/25
16:31
09/25/18
16:31
Hot Stocks
Oneok to construct additional NGL fractionation, pipeline capacity »

Oneok announced plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
09/25/18
09/25
16:30
09/25/18
16:30
Options
Preliminary option volume of 15.6M today »

Preliminary option volume…

MOR

MorphoSys

$27.13

0.315 (1.17%)

16:28
09/25/18
09/25
16:28
09/25/18
16:28
Hot Stocks
MorphoSys says licensee has begun study to test gselkumab in pediatric group »

MorphoSys announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NITE

Nightstar Therapeutics

$20.35

-0.97 (-4.55%)

16:26
09/25/18
09/25
16:26
09/25/18
16:26
Syndicate
Nightstar Therapeutics files to sell 4M American Depositary Shares »

Jefferies, Barclays…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

NITE

Nightstar Therapeutics

$20.35

-0.97 (-4.55%)

16:24
09/25/18
09/25
16:24
09/25/18
16:24
Syndicate
Nightstar Therapeutics files to sell 4M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

VSTM

Verastem

$7.15

-1.74 (-19.57%)

16:23
09/25/18
09/25
16:23
09/25/18
16:23
Hot Stocks
Breaking Hot Stocks news story on Verastem »

Verastem rises over 5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 05

    Oct

ICCC

Immucell

$8.35

-0.155 (-1.82%)

16:22
09/25/18
09/25
16:22
09/25/18
16:22
Hot Stocks
Immucell looks to bring mastitis treatment to market in 2020 »

ImmuCell announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ICCC

Immucell

$8.35

-0.155 (-1.82%)

16:22
09/25/18
09/25
16:22
09/25/18
16:22
Hot Stocks
Immucell receives fourth complete letter of NADA for Nisin treatment for cows »

Immucell announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

VSTM

Verastem

$7.15

-1.74 (-19.57%)

16:21
09/25/18
09/25
16:21
09/25/18
16:21
Hot Stocks
Verastem and CSPC Pharma sign license agreement to develop COPIKTRA in China »

Verastem and CSPC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 05

    Oct

LOXO

Loxo Oncology

$166.80

3.73 (2.29%)

16:21
09/25/18
09/25
16:21
09/25/18
16:21
Hot Stocks
Loxo Oncology announces LOXO-292 durability update »

Loxo Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 26

    Nov

  • 27

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
09/25/18
09/25
16:20
09/25/18
16:20
Options
Closing CBOE SPX and VIX Index summary for September 25th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$84.79

0.52 (0.62%)

16:19
09/25/18
09/25
16:19
09/25/18
16:19
Hot Stocks
Breaking Hot Stocks news story on Nike »

Nike slips 4.1% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

KBH

KB Home

$25.29

-0.24 (-0.94%)

16:19
09/25/18
09/25
16:19
09/25/18
16:19
Hot Stocks
Breaking Hot Stocks news story on KB Home »

KB Home rises over 4%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

TRN

Trinity Industries

$36.78

-0.37 (-1.00%)

16:19
09/25/18
09/25
16:19
09/25/18
16:19
Hot Stocks
Trinity Industries board approves separation of Arcosa »

Trinity Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CASH

Meta Financial

$84.15

1.45 (1.75%)

16:18
09/25/18
09/25
16:18
09/25/18
16:18
Hot Stocks
Meta Financial anounces Brent Turner will step down as EVP »

Meta Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTAS

Cintas

$212.99

1.81 (0.86%)

16:18
09/25/18
09/25
16:18
09/25/18
16:18
Earnings
Cintas raises FY19 EPS view to $7.19-$7.29 from $7.00-$7.15, consensus $7.16 »

Raises FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

NKE

Nike

$84.79

0.52 (0.62%)

16:18
09/25/18
09/25
16:18
09/25/18
16:18
Hot Stocks
Nike reports Q1 North America revenue $4.145B, up 6% »

Reports Q1 EMEA revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

MRCY

Mercury Systems

$53.93

1.17 (2.22%)

16:17
09/25/18
09/25
16:17
09/25/18
16:17
Hot Stocks
Mercury Systems receives $5.5M order »

Mercury Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
09/25/18
09/25
16:17
09/25/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KORS

Michael Kors

$68.01

1.3 (1.95%)

, CPRI

Capri Holdings

$0.00

(0.00%)

16:16
09/25/18
09/25
16:16
09/25/18
16:16
General news
Fly Intel: Wall Street's top stories for Tuesday »

Stocks opened in positive…

KORS

Michael Kors

$68.01

1.3 (1.95%)

CPRI

Capri Holdings

$0.00

(0.00%)

FB

Facebook

$164.94

-0.46 (-0.28%)

SQ

Square

$95.40

9.34 (10.85%)

PAYX

Paychex

$73.72

-0.84 (-1.13%)

ADP

ADP

$148.80

-0.32 (-0.21%)

SONC

Sonic

$43.46

6.85 (18.71%)

GM

General Motors

$33.57

-1.175 (-3.38%)

F

Ford

$9.39

-0.195 (-2.03%)

FCAU

Fiat Chrysler

$18.00

-0.315 (-1.72%)

BMWYY

BMW

$0.00

(0.00%)

XOXO

XO Group

$34.91

7.29 (26.39%)

ASNA

Ascena Retail

$4.47

0.45 (11.19%)

TGTX

TG Therapeutics

$5.13

-4.125 (-44.59%)

CTL

CenturyLink

$21.05

-1.85 (-8.08%)

TMUS

T-Mobile

$69.46

0.53 (0.77%)

S

Sprint

$6.40

0.01 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 01

    Oct

  • 02

    Oct

  • 02

    Oct

  • 04

    Oct

  • 04

    Oct

  • 11

    Oct

  • 22

    Oct

  • 28

    Oct

  • 31

    Oct

  • 06

    Nov

  • 07

    Nov

  • 12

    Nov

  • 13

    Nov

  • 26

    Nov

NKE

Nike

$84.79

0.52 (0.62%)

16:16
09/25/18
09/25
16:16
09/25/18
16:16
Hot Stocks
Nike reports Q1 Nike Brand revenue $9.4B, up 10% »

Revenues for the NIKE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CTAS

Cintas

$212.99

1.81 (0.86%)

16:16
09/25/18
09/25
16:16
09/25/18
16:16
Hot Stocks
Cintas reports Q1 organic growth rate up 5.4% from last year »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

NNI

Nelnet

$56.82

-0.79 (-1.37%)

16:16
09/25/18
09/25
16:16
09/25/18
16:16
Hot Stocks
Nelnet withdraws application with FDIC »

Nelnet announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.